Newsroom Articles Glossary SignalPoint Signal On-Call Home Subscribe to the Trendletter E-mail  Search        About Us             Services             Clients             Contact Us             עברית         Overview   Team   Signal America   Retail Advisory Panel   Medical Advisory Panel   Market Strategy   Partner & Sales Channel Development   Marketing Communications   Signal ON-CALL   Client List   Client Stories   Contact Info   Directions News   Kamada signs US distribution deal for emphysema drug Injectable AAT has already passed its Phase III clinical trial, and the agreement will come into effect when the FDA gives the drug marketing clearance Gali Weinreb, Globes[online] (25 Aug 2009) Drug development company Kamada Ltd. (TASE: KMDA) has signed a distribution agreement in the US worth a minimum of $15 million for the company's Alpha-1 Antitrypsin (AAT) protein for the treatment of congenital emphysema. The agreement applies only to the injectable version of the drug, while Kamada has reserved distribution rights to the inhalable version.   Directions     Privacy Policy     Site Map     Tel: +972.72.260.7000 ©2010 The Trendlines Group Ltd. All rights reserved. This site contains material copyrighted by third parties.